New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
StockNews.AI · 3 hours
AI Summary
Century Therapeutics reports CNTY-813 preclinical data showing durable glucose control (>8 months) in mice, immune evasion under alloimmune pressure, and robust manufacturing consistency. IND submission remains on track for 4Q2026, with initial first-in-human data expected in 2H2027, potentially delivering a functional cure for Type 1 diabetes without chronic immunosuppression.
Sentiment Rationale
Positive preclinical efficacy, immune-evasion tech, and a concrete IND timeline provide a meaningful near-term catalyst for IPSC valuation, despite lack of human data.
Trading Thesis
Bullish for IPSC on CNTY-813 progress; IND by 4Q2026 with data 2H2027, over 12–18 months.
Market-Moving
- IND 4Q2026 timing could drive IPSC upside into year-end.
- ADA data presentation underscores CNTY-813 differentiation vs existing therapies.
- Manufacturing consistency across 11 samples reduces scaling risk.
- In vivo durability and allo-immune pressure data support regulatory timing.
Key Facts
- CNTY-813 yields >8 months glucose control in mice. Potential T1D functional cure.
- Allo-Evasion 5.0 enables engraftment under allogeneic pressure. No immunosuppression needed.
- Phase 1 manufacturing established with consistent purity; IND 4Q2026 target.
- Beta cells >50% of CNTY-813; no tumorigenesis in >140 mice.
- IND data anticipated 4Q2026; initial data 2H2027; ADA presentation in New Orleans.
Companies Mentioned
- Century Therapeutics (IPSC): CNTY-813 preclinical data indicate potential functional cure for T1D; IND 4Q2026; 2H2027 data.
Industry News
Industry News: reports on CNTY-813 preclinical progress, manufacturing milestones, and near-term regulatory milestones for an IPSC-based therapy.